Bortezomib, Dexamethasone, and Fibroblast Growth Factor Receptor 3–Specific Tyrosine Kinase Inhibitor in t(4;14) MyelomaGuido Bisping(Boehringer Ingelheim (Germany)), Joachim Kienast(Boehringer Ingelheim (Germany))Clinical Cancer ResearchJanuary 15, 200910.1158/1078-0432.ccr-08-1612Cited by 32SaveCiteExport RISWatch citationsRelated PapersTargeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically defined subgroups|Blood|2005|36